Ask AI
ProCE Banner Activity

Closing the Gap Between Evidence and Practice: Adjuvant CDK4/6 Inhibitors in High-Risk HR-Positive/HER2-Negative Early Breast Cancer

Clinical Thought

The treatment landscape for high-risk HR-positive/HER2-negative early breast cancer continues to evolve, with emerging evidence and adjuvant CDK4/6 inhibitors creating new opportunities to reduce recurrence risk and improve long-term outcomes. This expert commentary explores how healthcare professionals can translate findings from pivotal clinical trials into individualized, guideline-concordant treatment decisions while navigating differences in patient eligibility, efficacy, and safety profiles.

Released: October 28, 2026

Share

Provided by

Provided by National Comprehensive Cancer Network in collaboration with Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by educational grants from Lilly and Novartis.

Lilly

Novartis

Partners

Decera Clinical Education

ProCE Banner

Target Audience

This activity has been designed to meet the educational needs of oncologists, nurse practitioners, physician associates, oncology nurses, pharmacists, and other healthcare professionals involved in the care of patients with HR-positive/HER2-negative early breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Collaborate with multidisciplinary colleagues to identify each patient with HR-positive/HER2-negative EBC who is eligible for CDK4/6 inhibitor treatment

  • Recommend the optimal CDK4/6 inhibitor treatment for each patient with HR-positive/HER2-negative EBC in alignment with NCCN Guidelines, high-level evidence, and expert-recommended best practices

  • Support open and frequent patient-clinician communication to enable effective counseling on the benefits vs potential risks of adjuvant CDK4/6 inhibitor treatment, reporting of patient-felt toxicities, and screening for barriers to adherence/persistence

  • Implement proactive toxicity monitoring, dose modification, and supportive care to enable patient adherence and persistence to CDK4/6 inhibitor treatment for HR-positive/HER2-negative EBC

Financial Disclosures

Primary Author

Jame Abraham, MD, FACP, has no relevant financial relationships to disclose.

Erin F. Cobain, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Gilead, Lilly, Novartis, Pfizer.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for drafting educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.